The recent approval of new drug therapies not only signals a new era in treatment of Alzheimer’s disease but also underscores the urgent need for innovations that will enable early screening for Mild Cognitive Impairment and accurate detection of all forms of dementia, including complex manifestations of Alzheimer’s disease.
Innovations currently in development or now emerging in the marketplace include a wide variety of tests and tools for cognitive and functional assessment and for biomarkers of disease found within the brain. These innovations may enable health care providers to assess patients more accurately and at a greater scale at a time when both primary care providers and neurologists are under great stress throughout the U.S. health care system.
See below for the panel recording held on April 11, 2024.